Matching targets for selective cancer therapy - PubMed (original) (raw)

Matching targets for selective cancer therapy

Mikhail V Blagosklonny. Drug Discov Today. 2003.

No abstract available

PubMed Disclaimer

Similar articles

• Nanoscale delivery systems for multiple drug combinations in cancer.
  Cao Y, Wang B, Lou D, Wang Y, Hao S, Zhang L. Cao Y, et al. Future Oncol. 2011 Nov;7(11):1347-57. doi: 10.2217/fon.11.109. Future Oncol. 2011. PMID: 22044207 Review.
• [Cancer chemotherapy in the future. Discussion].
  Akaza H, Sasaki T, Konishi T, Tsukuda M. Akaza H, et al. Gan To Kagaku Ryoho. 2003 Oct;30(10):1422-33. Gan To Kagaku Ryoho. 2003. PMID: 14594003 Japanese. No abstract available.
• [Precise pathological and molecular diagnosis is the premise of relevant anti-cancer targeted therapy].
  Zheng J. Zheng J. Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):433-4. Zhonghua Bing Li Xue Za Zhi. 2007. PMID: 17845751 Chinese. No abstract available.
• Drug delivery systems and combination therapy by using vinca alkaloids.
  Lee CT, Huang YW, Yang CH, Huang KS. Lee CT, et al. Curr Top Med Chem. 2015;15(15):1491-500. doi: 10.2174/1568026615666150414120547. Curr Top Med Chem. 2015. PMID: 25877096 Free PMC article. Review.
• Cancer research 2001: drug resistance, new targets and drug combinations.
  Broxterman HJ, Georgopapadakou N. Broxterman HJ, et al. Drug Resist Updat. 2001 Jun;4(3):197-209. doi: 10.1054/drup.2001.0216. Drug Resist Updat. 2001. PMID: 11768333

Cited by

• Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer.
  Lou S, Zhao Z, Dezort M, Lohneis T, Zhang C. Lou S, et al. ACS Omega. 2018 Aug 31;3(8):9210-9219. doi: 10.1021/acsomega.8b00949. Epub 2018 Aug 15. ACS Omega. 2018. PMID: 30197996 Free PMC article.
• Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.
  Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. Oncotarget. 2017 Dec 4;9(8):7774-7781. doi: 10.18632/oncotarget.22892. eCollection 2018 Jan 30. Oncotarget. 2017. PMID: 29487690 Free PMC article.
• Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
  Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ. Bokobza SM, et al. Oncotarget. 2014 Jul 15;5(13):4765-78. doi: 10.18632/oncotarget.2017. Oncotarget. 2014. PMID: 24946858 Free PMC article.
• Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model.
  Murakami T, Hiroshima Y, Miyake K, Hwang HK, Kiyuna T, DeLong JC, Lwin TM, Matsuyama R, Mori R, Kumamoto T, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Hoffman RM. Murakami T, et al. Cell Cycle. 2017 May 19;16(10):1008-1014. doi: 10.1080/15384101.2017.1315489. Epub 2017 Apr 25. Cell Cycle. 2017. PMID: 28441080 Free PMC article.
• Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse models.
  Park JY, Lee JY, Zhang Y, Hoffman RM, Bouvet M. Park JY, et al. Oncotarget. 2016 Apr 5;7(14):18262-8. doi: 10.18632/oncotarget.7576. Oncotarget. 2016. PMID: 26919100 Free PMC article.

MeSH terms